Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SETRAPED transmucosal midazolam for pediatric palliative sedation
2025-523840-11-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midazolam in refractory symptoms in pediatric palliative care, sponsored by Centre Léon Bérard. Primary endpoint: Primary efficacy of proportional palliative sedation. Planned start Jul 2026; status: authorised.
02
Drugs
midazolam
03
Conditions
refractory symptoms in pediatric palliative care
Beyond the preview
Go deeper on 2025-523840-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523840-11-00.